AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma. More: NICE backs AZ’ asthma biologic Fasenra Source: News
read moreUS regulators have approved the first treatment designed to mitigate the impact of a potential outbreak of smallpox caused by bioterrorism. More: FDA approves first smallpox therapy Source: News
read moreFour Democratic senators have published a report rebutting Novartis’ account of the details behind its consulting deal with Michael Cohen, President Donald Trump’s former attorney. More: Senators challenge Novartis' account of Cohen deal, calling it 'longer and more detailed' than
read moreWhile support from drug companies can be helpful for patients, sometimes support from others struggling with a disease can be even more helpful. So Bayer is offering both. More: Adempas maker Bayer connects hypertension patients with new mentoring group Source:
read moreAs Beijing and Washington exchange harsh words over President Trump’s renewed threat of additional tariffs, China is preparing to open up its pharma market further for a neighbor that it hasn’t historically had a good relationship with. More: As U.S.
read moreA ruling from the U.S. Patent and Trademark Office pushes Novartis’ exclusivity on Gilenya from 2019 to 2027. That will give Celgene more time to secure FDA approval for its Gilenya rival and persuade physicians that it’s a safer alternative
read more© 1994 - 2026 B.M. Pharmaceuticals